Biotechnology companies are preparing for another year of significant regulatory and commercial decisions. Federal proposals involving pharmaceutical pricing, international investment restrictions, and drug development agreements could affect how companies finance research, negotiate partnerships, and bring new medicines to market. These questions are particularly important for companies entering the U.S. market or expanding their relationships with international pharmaceutical manufacturers.
For emerging biotechnology businesses, legal and regulatory issues often arise before they have established a full internal legal department. Larger companies may already have in-house counsel but need additional assistance with specialized healthcare regulations, commercial agreements, or government policy. Knowing when to involve outside counsel can help management evaluate regulatory obligations before they affect financing, development timelines, or commercial relationships.
International Biotechnology Companies Entering the U.S. Market
European and UK biotechnology companies face additional considerations when entering the United States. A company developing a promising therapy may have completed substantial research in Europe but still need to understand how U.S. regulatory requirements, reimbursement arrangements, and pharmaceutical contracting practices will affect its commercial plans.
These considerations extend beyond FDA approval. Companies may need to evaluate Medicare and Medicaid reimbursement, pharmaceutical pricing policies, distribution arrangements, licensing agreements, and relationships with U.S. manufacturers or commercial partners. Federal policy developments involving MFN pricing and international investment restrictions can also affect how companies negotiate agreements and structure their U.S. operations.
LL&S advises companies on U.S. healthcare regulatory requirements and commercial legal matters, while Lanton Strategies International B.V. provides separate advisory services involving international pharmaceutical strategy, market access, pricing, reimbursement, and business development. Together, these capabilities allow companies to obtain legal advice and international commercial guidance through appropriately structured engagements.